{"id":11190,"date":"2021-05-31T00:00:00","date_gmt":"2021-05-31T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/sante-canada-approuve-la-premiere-et-la-seule-therapie-car-t-pour-le-traitement-du-myelome-multiple\/"},"modified":"2025-08-19T08:28:17","modified_gmt":"2025-08-19T13:28:17","slug":"sante-canada-approuve-la-premiere-et-la-seule-therapie-car-t-pour-le-traitement-du-myelome-multiple","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2021\/05\/31\/sante-canada-approuve-la-premiere-et-la-seule-therapie-car-t-pour-le-traitement-du-myelome-multiple\/","title":{"rendered":"SANT\u00c9 CANADA APPROUVE LA PREMI\u00c8RE ET LA SEULE TH\u00c9RAPIE CAR T POUR LE TRAITEMENT DU MY\u00c9LOME MULTIPLE"},"content":{"rendered":"<p>Bristol Myers Squibb Canada (BMS) a annonc\u00e9 aujourd&rsquo;hui que Sant\u00e9 Canada a accord\u00e9 une approbation conditionnelle (AC-C) pour ABECMAMC (id\u00e9cabtag\u00e8ne vicleucel; id\u00e9-cel) \u00e0 titre de premi\u00e8re et seule immunoth\u00e9rapie par des lymphocytes T porteurs de r\u00e9cepteurs antig\u00e9niques chim\u00e9riques (CAR T) dirig\u00e9e vers un antig\u00e8ne de maturation des lymphocytes B (BCMA) pour les adultes atteints de my\u00e9lome multiple (MM). ABECMAMC est indiqu\u00e9 pour le traitement des patients pr\u00e9sentant un my\u00e9lome multiple qui ont re\u00e7u au moins trois traitements ant\u00e9rieurs, y compris un agent immunomodulateur, un inhibiteur du prot\u00e9asome et un anticorps anti-CD38, et dont la maladie est r\u00e9fractaire au dernier traitement administr\u00e9.<\/p>\n<p><a href=\"https:\/\/www.newswire.ca\/fr\/news-releases\/sante-canada-approuve-abecma-mc-idecabtagene-vicleucel-la-premiere-et-la-seule-therapie-car-t-dirigee-vers-un-antigene-de-maturation-des-lymphocytes-b-bcma-pour-le-traitement-du-myelome-multiple-recidivant-et-refractaire-864308868.html\" target=\"_blank\" rel=\"noopener\">Lire le communiqu\u00e9 de presse<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bristol Myers Squibb Canada (BMS) a annonc\u00e9 aujourd&rsquo;hui que Sant\u00e9 Canada a accord\u00e9 une approbation conditionnelle (AC-C) pour ABECMAMC (id\u00e9cabtag\u00e8ne vicleucel; id\u00e9-cel) \u00e0 titre de premi\u00e8re et seule immunoth\u00e9rapie par des lymphocytes T porteurs de r\u00e9cepteurs antig\u00e9niques chim\u00e9riques (CAR T) dirig\u00e9e vers un antig\u00e8ne de maturation des lymphocytes B (BCMA) pour les adultes atteints de [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11190","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11190","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11190"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11190\/revisions"}],"predecessor-version":[{"id":31298,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11190\/revisions\/31298"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11190"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11190"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11190"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}